INCY vs. ZTS: Incyte vs. Zoetis Stock Comparison
How do Incyte (INCY) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Incyte (INCY) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while ZTS is classified in Pharmaceuticals.
| Profile Item | INCY | ZTS |
|---|---|---|
| Name | Incyte Corp. | Zoetis Inc. Class A Common Stock |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Pharmaceuticals |
| GICS Sub-Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 24.39 billion USD | 32.26 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | November 4, 1993 | February 1, 2013 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INCY | ZTS |
|---|---|---|
| Total Return (1Y) | 14.06% | -30.10% |
| Total Return (3Y, Annualized) | 32.03% | -20.42% |
| Total Return (5Y, Annualized) | 12.69% | -16.87% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INCY | ZTS |
|---|---|---|
| Volatility (1Y, Annualized) | 33.19% | 38.23% |
| Beta (5Y) | 0.78 | 0.66 |
| Max Drawdown (5Y) | -40.50% | -70.45% |
| Avg. Volume (3M) | 1.58M | 4.65M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INCY | ZTS |
|---|---|---|
| Sharpe Ratio (1Y) | 0.29 | -0.90 |
| Sortino Ratio (1Y) | 0.46 | -1.10 |
Profitability
ROE (TTM)
Both Incyte (INCY) at 7.84% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
57.63%
- Max
- 109.18%
- ZTS
- 57.63%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Zoetis (ZTS) at 26.41% keeps the most of each sales dollar — above its industry’s net margin range — and Incyte (INCY) at 6.71% also retains a top-quartile share.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.41%
- ZTS
- 26.41%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Incyte (INCY) at 33.72% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
38.19%
- Max
- 83.12%
- ZTS
- 38.19%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | INCY | ZTS |
|---|---|---|
| ROE (TTM) | 7.84% | 57.63% |
| ROA (TTM) | 17.78% | 14.87% |
| Net Margin (TTM) | 6.71% | 26.41% |
| Operating Margin (TTM) | 33.72% | 38.19% |
| Gross Margin (TTM) | 56.02% | 71.65% |
Growth
Revenue Growth
Both Incyte (INCY) at 21.22% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than Zoetis (ZTS) at 10.05%, which is closer to a typical peer reading.
Growth Metrics
| Metric | INCY | ZTS |
|---|---|---|
| Revenue Growth (YoY) | 21.22% | 2.28% |
| Revenue Growth (3Y CAGR) | 14.84% | 5.42% |
| EPS Growth (YoY) | 4,173.33% | 10.05% |
| EPS Growth (3Y CAGR) | 61.56% | 10.27% |
Financial Strength
Current Ratio (MRQ)
Incyte (INCY) at 3.84 keeps current ratio within its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ZTS.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ZTS
- 2.35
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower quartile, while Zoetis (ZTS) at 2.80 is above its industry debt-to-equity ratio range.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.80
- ZTS
- 2.80
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INCY | ZTS |
|---|---|---|
| Current Ratio (MRQ) | 3.84 | 2.35 |
| Debt / Equity (MRQ) | 0.01 | 2.80 |
| Net Debt / EBITDA | -1.88 | 1.92 |
Dividends
Dividend Yield (TTM)
Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.55%
- ZTS
- 2.55%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.24%
- ZTS
- 35.24%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INCY | ZTS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 2.55% |
| Dividend Payout Ratio (TTM) | 0.00% | 35.24% |
Valuation
P/E Ratio (TTM)
Zoetis (ZTS) at 13.50 is near its industry’s usual P/E ratio, while Incyte (INCY) at 61.05 sits in the richer quartile — INCY needs stronger growth or earnings quality to justify the premium.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.50
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- ZTS
- 13.50
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Incyte (INCY) at 4.06 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.40
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ZTS
- 3.40
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ZTS
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.80
- Max
- 13.53
- ZTS
- 9.80
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INCY | ZTS |
|---|---|---|
| P/E Ratio (TTM) | 61.05 | 13.50 |
| P/S Ratio (TTM) | 4.06 | 3.40 |
| P/B Ratio (MRQ) | 4.33 | 9.80 |
| Free Cash Flow Yield (TTM) | 5.28% | 6.36% |